- Home
- HROW vs VRDN Comparison
HROW vs VRDN Comparison
Compare HROW & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- VRDN
- Stock Information
- Founded
- HROW 1998
- VRDN 2006
- Country
- HROW United States
- VRDN United States
- Employees
- HROW N/A
- VRDN N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- VRDN Medical Specialities
- Sector
- HROW Health Care
- VRDN Health Care
- Exchange
- HROW Nasdaq
- VRDN Nasdaq
- Market Cap
- HROW 1.4B
- VRDN 1.6B
- IPO Year
- HROW N/A
- VRDN N/A
- Fundamental
- Price
- HROW $36.81
- VRDN $23.32
- Analyst Decision
- HROW Strong Buy
- VRDN Strong Buy
- Analyst Count
- HROW 7
- VRDN 10
- Target Price
- HROW $68.50
- VRDN $36.78
- AVG Volume (30 Days)
- HROW 804.0K
- VRDN 1.4M
- Earning Date
- HROW 11-10-2025
- VRDN 11-13-2025
- Dividend Yield
- HROW N/A
- VRDN N/A
- EPS Growth
- HROW N/A
- VRDN N/A
- EPS
- HROW N/A
- VRDN N/A
- Revenue
- HROW $227,661,000.00
- VRDN $305,000.00
- Revenue This Year
- HROW $43.92
- VRDN N/A
- Revenue Next Year
- HROW $41.22
- VRDN $34,044.63
- P/E Ratio
- HROW N/A
- VRDN N/A
- Revenue Growth
- HROW 47.69
- VRDN 5.90
- 52 Week Low
- HROW $20.85
- VRDN $9.90
- 52 Week High
- HROW $54.19
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- HROW 38.13
- VRDN 60.55
- Support Level
- HROW $36.20
- VRDN $21.65
- Resistance Level
- HROW $39.77
- VRDN $23.34
- Average True Range (ATR)
- HROW 1.89
- VRDN 1.07
- MACD
- HROW -0.40
- VRDN -0.07
- Stochastic Oscillator
- HROW 9.98
- VRDN 60.84
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).